Table 3.

Treatment response to bintrafusp alfa (N = 30)

	Independent review committee	Investigator
Confirmed best overall response, n (%)
Complete response  Partial response  Stable disease  Non-complete response/non-progressive disease  Progressive disease  Not evaluable	0 3 (10.0) 3 (10.0) 3 (10.0) 18 (60.0) 3 (10.0)	0 6 (20.0) 5 (16.7) 0 17 (56.7) 2 (6.7)
Confirmed ORR, n (%) 95% CI	3 (10.0) 2.1–26.5	6 (20.0) 7.7–38.6
DCR, n (%) 95% CI	9 (30.0) 14.7–49.4	11 (36.7) (19.9–56.1)
Median duration of response, months (range)	7.0 (2.8–8.3+)	7.0 (4.2+–11.1+)
ORR by tumor cell PD-L1 expression, n/N (%)a
Positive  Negative  Not evaluable	3/14 (21.4) 0/13 (0) 0/3 (0)	2/14 (14.3) 3/13 (23.1) 1/3 (33.3)

CI confidence interval, DCR disease control rate, ORR objective response rate, PD-L1 programmed death-ligand 1

^aA threshold of 1% was used to characterize tumors as either PD-L1 positive (≥ 1%) or negative (< 1%) using an anti–PD-L1 antibody clone 73-10